1. Mendelian
  2. Rare Diseases
  3. ANGIOEDEMA INDUCED BY ACE INHIBITORS, SUSCEPTIBILITY TO; AEACEI

Angioedema Induced By Ace Inhibitors, Susceptibility To; Aeacei

Table of contents:

Description

Approximately 40 million people take ACE inhibitors (ACEi) to treat hypertension and cardiovascular disease. A small proportion of white patients who take ACEi (0.1-0.7%) develop angioedema (AEACEI) (Israili and Hall, 1992; Vleeming et al., 1998), a potentially life-threatening side effect characterized by swelling of the face, lips, tongue, and airway that can lead to suffocation and death if severe. ACEi-associated angioedema is 4 to 5 times more prevalent among African Americans (Brown et al., 1996; Coats, 2002). Other risk factors include female sex, smoking, immunosuppressant therapy, and seasonal allergies. The pathophysiology of ACEi-associated angioedema is thought to be related to increased circulating bradykinin, which is normally degraded by ACE. During pharmacologic ACE inhibition, bradykinin is primarily degraded by aminopeptidase P (summary by Duan et al., 2005 and Woodard-Grice et al., 2010). Aminopeptidase P is encoded by 3 genes: XPNPEP1 (OMIM ) on chromosome 10q25, XPNPEP2 (OMIM ) on chromosome Xq25, and XPNPEP3 (OMIM ) on chromosome 22q13.

Genes related to Angioedema Induced By Ace Inhibitors, Susceptibility To; Aeacei

  • XPNPEP2

View recommended genes panels

Clinical Features

Phenotypes and symptoms related to Angioedema Induced By Ace Inhibitors, Susceptibility To; Aeacei

  • Hypertension
  • Abnormality of the cardiovascular system
  • Angioedema

Incidence and onset information

— Currently we don't have prevalence information about this disease (Not enough data available about incidence and published cases.)
— No data available about the known clinical features onset.

Researches and researchers

Currently, we don't have any information about doctors, researches or researchers related to this disease. Please contact us if you would like to appear here.

Angioedema Induced By Ace Inhibitors, Susceptibility To; Aeacei Recommended genes panels

Panel Name, Specifity and genes Tested/covered
XPNPEP2.

By Fulgent Genetics Fulgent Genetics (United States).

XPNPEP2
Specificity
100 %
Genes
100 %

You can get up to -7 more panels with our dedicated tool

Learn more

Sources and references

You can check the following sources for additional information.

OMIM MESH Rare Disease Search Engine

If you liked this article maybe you will also find interesting the following in-depth articles about other rare diseases, like RECESSIVE MITOCHONDRIAL ATAXIA SYNDROME MAY-HEGGLIN ANOMALY; MHA EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1 WILSON-TURNER X-LINKED MENTAL RETARDATION SYNDROME; WTS THROMBOPHILIA DUE TO THROMBOMODULIN DEFECT; THPH12 AUTOINFLAMMATION, ANTIBODY DEFICIENCY, AND IMMUNE DYSREGULATION, PLCG2-ASSOCIATED; APLAID NETHERTON SYNDROME; NETH